Tandem Therapeutics develops precision peptide drug conjugates that target disease‑associated extracellular matrix alterations to treat fibrosis‑driven diseases. Their platform uses matrix‑targeting peptides to overcome the ECM barrier and deliver therapeutics directly to fibrotic tissue. The approach combines matrix mechanobiology, structural protein‑protein interaction insights, and disease modeling to create first‑in‑class anti‑fibrotic therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug development is heavily focused on targeting cells, often overlooking the critical role of the extracellular matrix (ECM) in disease progression and therapeutic resistance, particularly in fibrotic diseases and cancers. The presence of excessive matrix proteins hinders drug access and efficacy.
Solution
Tandem Therapeutics is developing conditionally targeted therapies that overcome the extracellular matrix barrier to treat fibrosis and fibrotic cancers. The company leverages evolutionarily optimized matrix targeting peptides (MTPs) to selectively target disease-associated matrix alterations, unlocking previously inaccessible druggable targets. By understanding matrix mechanobiology and its relation to disease progression, Tandem Therapeutics is creating a pipeline of efficacious and safer therapies that can modulate the course of fibrosis-driven diseases. Their approach aims to improve drug delivery and efficacy by addressing the unique mechanical fingerprint of the ECM.
Target Audience
The primary target audience includes patients suffering from fibrotic diseases and fibrotic cancers, as well as pharmaceutical companies seeking innovative approaches to overcome therapeutic resistance associated with the extracellular matrix.
Features
- Matrix Targeting Peptides (MTPs) that conditionally target disease-associated matrix alterations
- Selective targeting of the extracellular matrix to enhance drug delivery and efficacy
- Pipeline of therapies for fibrotic diseases and fibrotic cancers
- Leverages insights into protein-protein interactions, matrix mechanobiology, and disease modeling
- Development of peptide drug conjugates to precision target and treat fibrosis-driven diseases